Our previous work showed that bacteria-derived AI-2 was associated with tumour immunity in CRC patients through inducing tumour-associated macrophages and reducing CD4/CD8 ratio in a TNFSF9-dependent manner [20]. This evidence concerns the gene CD8A and neoplasm.